Pathogen Genomics and Bioinformatics Support

Added: Jun 01, 2016 2:40 pm The Centers for Disease Control and Prevention (CDC), National Center for Emerging and Zoonotic Infectious Diseases contemplates award of a firm-fixed-price sole source Contract to The Translational Genomics Research Institute, Phoenix, AZ 85004-2274 for support services in support of CDC's Advanced Molecular Detection Initiative including high throughput sequencing and laboratory analysis, bioinformatic support for phylogenetics and comparative microbial genomics and outbreak support.

The Translational Genomics Research Institute (TGen North) is a leader in pathogen genomics and infectious disease bioinformatics, and has developed the necessary sequence collections, laboratory techniques, bioinformatics tools, resources and expertise that are needed for this specific scope of work. TGen North has extensive experience in working with federal and state public health laboratories on genomic analysis, molecular surveillance and outbreak investigations for pathogenic fungi and molds including Exserohilum spp., Apophysomyces spp. and Coccidioides spp.; the characterization of biothreat agents such as Yersinia pestis and Bacillus anthracis; and in the investigation and characterization of healthcare-associated and highly-resistant pathogens such as carbapenem-resistant Enterobacteriaceae (CRE) and methicillin-resistant Staphylococcus aureus. This unique combination of laboratory capacity, bioinformatic infrastructure, resources and expertise is so specialized that it cannot be obtained from any other source without incurring significant cost or delay. No other vendor has been identified that can adequately meet the CDC's needs within the required timeframe.

The North American Industrial Classification Standards (NAICS) Code is 541690 and Standard Business Size of $15 Million. This acquisition will be negotiated under the authority of FAR 6.302-1 as only one responsible source will satisfy agency requirements. CDC is not requesting competitive proposals and no solicitation is available. Interested parties who believe they possess the capabilities to satisfy this requirement should indicate their interest in writing and submit a capability statement demonstrating their ability to meet this requirement no later than 3:00 PM Eastern Standard Time, on June 16, 2016. Determination not to compete this proposed action based on responses to this notice is solely within the discretion of the Government. Respondents will assume all financial costs for preparing a response to this notice. The U.S. Government assumes no financial obligation for the preparation and distribution of prepared responses. Inquiries may be sent to Patrick Winders via email at vxx6@cdc.gov